



Charlotte Kloft

Contact

Charlotte Kloft

Publications (13)

Nassar Y, Ojara F, Pérez-Pitarch A, Geiger K, Huisinga W, Hartung N, Michelet R, Holdenrieder S, Jörger M, Kloft C. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. *Cancers (Basel)* 2023; 15

Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Jörger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. *CPT Pharmacometrics Syst Pharmacol* 2023; 12:1714-1725.

Mc Laughlin A, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland S, Huitema A, Steeghs N, Müller L, Fuxius S, Illerhaus G, Jörger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. *Cancers (Basel)* 2021; 13

Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Klopp-Schulze L, Michelet R, Kloft C. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. *Cancers (Basel)* 2021; 13

Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Michelet R, Klopp-Schulze L, Kloft C. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. *Pharmaceuticals (Basel)* 2021; 14

Muth M, Ojara F, Kloft C, Jörger M. Role of TDM-based dose adjustments for taxane anticancer drugs. *Br J Clin Pharmacol* 2020; 87:306-316.

Ojara F, Henrich A, Frances N, Huisinga W, Hartung N, Jörger M, Kloft C. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. *J Pharmacol Exp Ther* 2020; 375:430-438.

Mueller-Schoell A, Schwab M, Zgheib N, Tfayli A, Chowbay B, Chen S, Eccles D, Copson E, Mathijssen R, Koolen S, Neven P, Jörger M, Huisinga W, Brauch H, Michelet R, Mürdter T, Schroth W, Klopp-Schulze L, Kloft C. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. *Clin Pharmacol Ther* 2020; 108:661-670.

Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen S, Mathijssen R, Jörger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. *Front Pharmacol* 2020; 11:283.

Klopp-Schulze L, Jörger M, Wicha S, Ter Heine R, Csajka C, Parra-Guillen Z, Kloft C. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. *Clin Pharmacokinet* 2018; 57:229-242.

Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. *Basic Clin Pharmacol Toxicol* 2017; 121:309-315.

Henrich A, Jörger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. *J Pharmacol Exp Ther* 2017; 362:347-358.

Klopp-Schulze L, Jörgen M, Wicha S, Parra-Guillen Z, Kloft C. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
. Int J Clin Pharmacol Ther 2016

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch